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INTRODUCTION
Preeclampsia affects about 5-8 percent of pregnancies, re-
sulting in substantial maternal and neonatal morbidity and
mortality. Although the etiology remains unclear, the clinical
features associated preeclampsia may be initiated by placen-
tal factors that enter the maternal circulation and may cause
endothelial dysfunction resulting in hypertension and pro-
teinuria (1-3). For a fetus to develop normally, it must receive
sufficient oxygen and nutrients from the maternal circulation
(4). These are supplied via the maternal spiral arteries in the
uterus. In preeclampsia, pseudo-vasculogenesis is defective,
and the resultant placental ischemia has been proposed to
trigger the release of unknown placenta-derived factors. The
latter are thought to induce systemic endothelial dysfunction
and thereby contribute to the renal, cardiovascular and neu-
rological problems associated with preeclampsia. 
Vascular endothelial growth factor (VEGF) binds with high
affinity to two tyrosine kinase receptors, the fms-like tyro-
sine kinase (Flt-1 or VEGFR-1) and the kinase domain recep-
tor (KDR or VEGFR-2), which are produced predominant-
ly by endothelial cells (5-7). Soluble Flt-1 (sFlt-1) is a splice
variant of the Flt-1 lacking the transmembrane and cytoplas-
mic domains. Thus, this isoform binds VEGF and inhibits
its biologic activities as a potent VEGF antagonist (7, 8).
Several studies have demonstrated that circulating total
VEGF concentration is significantly elevated in women with
preeclampsia (9-11). However, recent studies have demon-
strated that biologically active free VEGF concentrations were
decreased in women with preeclampsia and that sFlt-1 con-
centrations were elevated in women with preeclampsia (1, 2,
12, 13). The investigators suggest that causes of endothelial
dysfunction in preeclampsia are not the increased total VEGF
level, but the decreased free VEGF (2). Nevertheless, VEGF
has many characteristics required for a candidate for a circu-
lating factor important to the development of preeclampsia.
It induces vascular permeability and also promotes coagula-
tion, two characteristic features of preeclampsia (2, 5). More-
over, in myographic studies, incubation of myometrial resis-
tance arteries with VEGF resulted in a reduction of endothe-
lium-dependent relaxation that mimicked the reduction in-
duced by plasma from women with preeclampsia (14). 
In order to clarify the role of VEGF in pathogenesis of pre-
eclampsia, we measured total VEGF, free VEGF and sFlt-1
concentrations at the same time and determined their rela-
tionships.
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The Levels of Circulating Vascular Endothelial Growth Factor and
Soluble Flt-1 in Pregnancies Complicated by Preeclampsia
To evaluate the role of vascular endothelial growth factor (VEGF) in the pathogen-
esis of preeclampsia, we measured total VEGF, free VEGF and soluble Flt-1 (sFlt-
1) concentrations and determined their relationships. Maternal serum samples were
collected from 20 patients with preeclampsia and 20 normotensive women with un-
complicated pregnancies matched with the patients with preeclampsia for gestational
age and parity. The serum concentrations of total VEGF (2.39± ±0.75 vs. 0.28± ±
0.14) and sFlt-1 (934.5± ±235.5 vs. 298.0± ±161.2) were significantly increased in
the patients with preeclampsia compared to the women with uncomplicated preg-
nancies. However the serum concentration of free VEGF (21.5± ±6.3 vs. 134.0± ±
16.3) was lower in patients with preeclampsia. There was a positive correlation bet-
ween the serum concentrations of total VEGF and sFlt-1 with systolic and diastolic
blood pressure, respectively. There was a negative correlation between the serum
concentration of free VEGF and systolic and diastolic blood pressure. There was a
strong negative correlation between free VEGF and sFlt-1 concentrations. In con-
clusion, we found VEGF and sFlt-1 were related to the pathogenesis of preeclamp-
sia. Although reduced concentrations of free VEGF might interfere with endothelial
cell function and survival, further studies are required to clarify its specific role in the
pathogenesis of preeclampsia. 
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MATERIALS AND METHODS
From May 2002 to December 2003 maternal serum sam-
ples were collected from 20 preeclamptic patients either before
the onset of labor or prior to medical intervention, at Korea
University Medical Center, Guro Hospital, Seoul, Korea.
Serum samples were also obtained from 20 normotensive
women with uncomplicated pregnancies, who were matched
with the preeclamptic patients for gestational age and pari-
ty. The diagnosis of preeclampsia was based on a blood pres-
sure of at least 140/90 mmHg on two or more separate occa-
sions and the development of proteinuria of at least 300 mg
in a 24 hr urine collection, or the presence of greater than 2+
protein on a catheterized specimen (15). Any woman with a
history of chronic hypertension, renal disease, diabetes mel-
litus, or vascular disease was excluded from the study.
Subjects were recruited with a protocol approved by the
institutional review board and written informed consent was
obtained from all of the participants. Venipuncture was per-
formed and blood was collected into tubes containing clot
activator and separator gel. The samples were centrifuged at
3,000 rpm for 20 min and the serum was then stored in ali-
quots at -70℃. The total VEGF was measured in duplicates
using a competitive enzyme immunoassay (CEIA; Accucyte
�
Human VEGF EIA, CytImmune Science, Inc., Rockville,
MD, U.S.A.). The detection range was from 0.195 to 200.0
ng/mL and intraassay variation and interassay variation were
8.9% and 11.1%, respectively. Free VEGF and sFlt-1 were
measured by a sandwich-type enzyme-linked immunosorbent
assay (ELISA; Quantikine
�human VEGF, Quantikine
�human
sVEGF R1, R&D Systems Inc., Minneapolis, MN, U.S.A.).
The minimum detectable dose of the free VEGF was less than
9 pg/mL and the intraassay variation and interassay variation
were 5.4% and 7.3%, respectively. The minimum detectable
level of the sFlt-1 was from 1.5-13.3 pg/mL and intraassay
variation and interassay variation were 3.2% and 7.6%, res-
pectively.
Demographic and clinical data were compared using Mann-
Whitney U test. Mann-Whitney U test was used to determine
the difference, in levels of total and free VEGF and sFlt-1,
between the two groups studied. ANOVA and linear regres-
sion analyses were used to investigate relationships. Statisti-
cal significance was assumed at a pvalue of <0.05. Data were
analyzed using SPSS program (Statistical Package for Social
Science, release 12.0; SPSS, Inc., Chicago, IL, U.S.A.).
RESULTS
There were no significant differences observed in maternal
age, parity and gestational age at blood sampling, between
the two groups studied (Table 1). As expected, systolic and
diastolic blood pressure were significantly higher in preeclamp-
tic patients (systolic 170±21.5 vs. 115.2±9.4 mmHg, p<
0.0001; diastolic 109.5±16.0 vs. 72.6±7.5 mmHg, p<
0.0001). Neonatal birth weight was significantly higher in
unaffected pregnant women (3.09±0.2 kg vs. 2.27±0.75
kg, p<0.001). Preeclamptic patients had a higher serum con-
centration of total VEGF and sFlt-1 compared to women with
unaffected normotensive pregnancies (total VEGF 2.39±0.75
ng/mL vs. 0.28±0.14 ng/mL, p<0.001; sFlt-1 934.5±235.5
pg/mL vs. 298.0±161.2 pg/mL, p<0.0001) (Fig. 1A, B).
However, the serum concentration of free VEGF was found
to be lower in preeclamptic patients (21.5±6.3 pg/mL vs.
134.0±16.3 pg/mL, p<0.001) (Fig. 1C). There was a positive
correlation between the serum concentration of total VEGF
and systolic and diastolic blood pressure (systolic pressure
r=0.818, p<0.0001; diastolic pressure r=0.749, p<0.0001);
and a positive correlation was also observed for sFlt-1 (systolic
pressure r=0.712, p<0.001; diastolic pressure r=0.725, p<
Values are given as mean±SD.
Statistical significance was assessed using the Mann-Whitney U test. 
NS, non-significance; GA, gestational age; BP, blood pressure.
Preeclampsia Unaffected
pregnancy
p
Age (yr) 29.8±4.7 30±3.6 NS
Parity 0.42 0.37 NS
GA (weeks) 35.4±3.2 35.8±3.2 NS
BP (mmHg)
Systolic 170±21.5 115.2±9.4 <0.0001
Diastolic 109.5±16.0 72.6±7.5 <0.0001
Birth weight (kg) 2.27±0.75 3.09±0.2 <0.001
Table 1. Clinical characteristics of the study population 
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Fig. 1. Distribution of Total VEGF levels (A), sFlt-1 levels (B), and Free VEGF levels in serum (C). P, preeclampsia; U, unaffected pregnancy.
Difference were significant: (A) p<0.001, (B) p<0.0001, (C) p<0.001. Values are given as mean±SD.
Statistical significance was assessed using Mann-Whitney U test.
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0.001) (Fig. 2A, B). There was a negative correlation between
the serum concentration of free VEGF and systolic and dias-
tolic pressure (systolic pressure r=-0.826, p<0.0001; diastolic
pressure r=-0.814, p<0.0001) (Fig. 2C). There was also a nega-
tive correlation between the serum concentration of free VE-
GF and sFlt-1 (r=-0.841, p<0.0001) (Fig. 2D). 
In addition, we found a positive correlation between the
serum concentration of total VEGF and proteinuria (r=0.187,
p<0.458), and a negative correlation observed between the
serum concentration of free VEGF and proteinuria (r=-0.254,
p<0.326). However, there was no significant negative corre-
lation with sFlt-1, and none of these correlations were statis-
tically significant (p>0.05).
DISCUSSION
VEGF is an endothelial cell-specific growth factor that
induces endothelial proliferation and chemotaxis, and stim-
ulates new blood vessel formation. In addition to angiogen-
esis, VEGF is believed to increase microvascular permeabili-
ty and also promote coagulation, two characteristic features
of preeclampsia (16). Although several studies have demon-
strated that circulating VEGF concentrations are significantly
elevated in women with preeclampsia, recent studies have
shown that the levels of serum free VEGF decrease in patients
with preeclampsia. This discrepancy could be explained by
the fact that VEGF-protein complexes are undetectable by
the sandwich-type ELISA because there is a substantial increase
in circulating VEGF binding proteins during pregnancy (16,
17). All prior studies reporting on decreased VEGF have used
an ELISA kit, which measures free (unbound) VEGF (17, 18),
whereas all studies reporting on an increased VEGF in pree-
clampsia used either a radioimmunoassay or an ELISA system
measuring total (bound and unbound) VEGF (19-21).
It is known that there are two main stores for circulating
VEGF. One is the platelet which takes up VEGF and releas-
es it on activation in vivo or in vitro; the other is the plasma
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Fig. 2. (A) There was a positive correlation between the serum concentration of total VEGF and systolic pressure and diastolic pressure. (B)
Positive correlation between the serum concentration of sFlt-1 and systolic pressure and diastolic pressure. (C) Negative correlation between
serum concentration of free VEGF and systolic pressure and diastolic pressure. (D) Negative correlation between serum concentration
of free VEGF and serum concentration of sFlt-1.
Difference were siginificant: (A) p<0.0001, (B) p<0.001, (C) p<0.0001, (D) p<0.0001. Values are given as mean±SD.
Statistical significance was assessed using the ANOVA and linear regression analyses.
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protein, namely  2-macroglobulin ( 2-M) and sFlt-1, which
are known to bind VEGF. The sFlt-1 protein is a splice vari-
ant of the VEGF receptor; Flt1 lacks the transmembrane and
cytoplasmic domains, and acts as a potent VEGF and placen-
tal growth factor (PlGF) antagonist (22). It has been recently
reported that placental sFlt1 mRNA is up-regulated in pree-
clampsia, leading to increased systemic levels of sFlt1 that
fall after delivery (2). The study also showed that increased
circulating sFlt1, in patients with preeclampsia, was associ-
ated with decreased circulating levels of free VEGF and PlGF;
this has been shown to cause endothelial dysfunction in vitro
that can be rescued by exogenous VEGF and PlGF (2). In-
deed, a role for blockade of VEGF action, in the pathophys-
iology of preeclampsia, has been suggested recently by sev-
eral studies in both animals and humans. Administration of
anti-VEGF compounds can induce hypertension and protein-
uria in nonpregnant animals and humans enrolled in anti-
angiogenic trials. Moreover administration of sFlt-1 to preg-
nant animals has been shown to induce the clinical features
of preeclampsia, including hypertension, proteinuria, and
glomerular endotheliosis (8).
Experimental evidence suggests that the serum from nor-
mal pregnant women is capable of inducing endothelial cells
to form tube-like structures, a biologic effect inhibited by
adding sFlt-1. By contrast, serum from preeclamptic patients
has been shown to inhibit endothelial tube formation. How-
ever this process can be restored by adding VEGF and PlGF.
The inhibition effect from the serum of women with pre-
eclampsia disappeared after delivery. This suggests that a fac-
tor may be released by the placenta. These observations sup-
port the concept that the angiogenic properties, from the
serum of preeclamptic patients may result from the block-
ade of VEGF by sFlt-1 (2, 8). 
Our study indicates that women with preeclampsia have
a higher serum concentration of sFlt-1 compared to unaf-
fected pregnant women. In addition, we observed that serum
concentration of total VEGF was higher in women with pre-
eclampsia than in unaffected pregnancies, while serum con-
centration of free VEGF was lower in women with preeclamp-
sia than in unaffected pregnant women. 
Although reduced concentrations of free VEGF could inter-
fere with endothelial cell function and survival (2, 8), there is
indirect evidence to support that VEGF itself mediates en-
dothelial cell activation in preeclampsia. In an in vitro study,
VEGF induced a significant concentration-dependent increase
in prostacyclin production; analogous to the acute effects of
plasma from patients with preeclampsia; the increase in pro-
stacyclin production, induced by plasma from women with
preeclampsia, could be inhibited by anti-VEGF antibody (23,
24). In addition, VEGF has been reported to increase the nit-
ric oxide production by human endothelial cells (25). There
are other important findings in ex vivo models using the tech-
nique of wire myography. Ashworth et al. demonstrated that
plasma from women with preeclampsia alters the endothelial
function of myometrial resistance arteries, compared to women
with uncomplicated pregnancies, by demonstrating a reduc-
tion in the relaxation of pre-constricted vessels (26). Similarly,
incubation of myometrial resistance vessels from normal preg-
nant women with VEGF resulted in a reduction of endothe-
lium-dependent relaxation, and this mimicked the reduction
induced by plasma from women with preeclampsia (14).
It remains to be proven whether changes in the concentra-
tion of free VEGF truly reflect functional VEGF in vivo, rel-
ative to degradation rates and altered binding by proteins.
Circulating VEGF exists in a free and bound form which
binds to binding proteins. sFlt-1 and  2-M are known to be
binding proteins of VEGF. Out of the total VEGF, only a
small portion of VEGF is bound to sFlt-1 in vivo. Another
major potential VEGF-binding protein is  2-M. Whereas
sFlt-1 has been known as a potent VEGF antagonist, it is not
clear how  2-M affects VEGF function (5, 27). Recently, Bha-
ttacharjee et al. demonstrated that under physiological condi-
tions,  2-M did not affect the ability of VEGF to induce cell
proliferation or up-regulate Ca2+ (28). We also demonstrated
VEGF-induced ET-1 up-regulation was inhibited by sFlt-1,
but not by  2-M in human umbilical vein endothelial cells
(29). Therefore, VEGF bound with  2-M might preserve bio-
logic action. Considering  2-M is present in human plasma
at a higher concentration (2-4 mg/mL) than sFlt-1, if VEGF
bound with  2-M preserves its biologic action, increased total
VEGF may contribute to the pathogenesis of preeclampsia.
However, further studies are required to support this hypoth-
esis. The limitations of this study include its small size. Des-
pite the small sample size, the results were statistically sig-
nificant. A larger study enrolling additional subjects would
likely provide the additional power needed to discern signifi-
cant difference of the two groups studied.
In summary, we have demonstrated a marked increase in
circulating sFlt-1 and total VEGF concentration in patients
with preeclampsia, accompanied by a decrease in circulating
free VEGF levels. These observations suggest an important
role for VEGF and its soluble receptor in the pathogenesis of
preeclampsia. However,  2-M, another VEGF-binding pro-
tein, has been shown to be elevated in pregnancy; it is not
clear how  2-M affects VEGF function to date. Therefore,
further studies are needed to evaluate the interaction between
2-M and VEGF.
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